







an Open Access Journal by MDPI

# The 10th Anniversary of *Vaccines*—Cancer Vaccines and Immunotherapy

Guest Editor:

# **Dr. Subbaya Subramanian**Department of Surgery, Lipiyoreity of Minnesota

University of Minnesota, Minneapolis, MN 55455, USA

Deadline for manuscript submissions:

closed (31 March 2023)

### **Message from the Guest Editor**

In 2022, we will celebrate the 10th anniversary volume of the journal *Vaccines* (ISSN 2076-393X).

Vaccines is an international, peer-reviewed, quick-refereeing, open access journal published online by MDPI, Basel, Switzerland. Vaccines is indexed by SCIE, PubMed (NLM), as well as others. The Impact Factor for this journal is 4.422, and it ranks 74/162 (Q2) in "Immunology" and 63/140 (Q2) in "Medicine, Research & Experimental Pharmacology" in Web of Science. The inaugural issue was released in 2013, and in 2020, we published the 1000th paper in this journal. In 2021, we achieved our goal of publishing 1200 papers in one year. Vaccines is definitely a rapidly developing journal.

This Special Issue will include high-quality papers on topics within the broad scope of *Vaccines*. We will consider manuscripts that investigate immunology and vaccinology against cancer. It is our pleasure to invite you to contribute an original research paper or a comprehensive review article for peer review and possible publication in *Vaccines*.













an Open Access Journal by MDPI

### **Editor-in-Chief**

#### Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

## **Message from the Editor-in-Chief**

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

#### **Author Benefits**

**Open Access:** free for readers, with <u>article processing charges (APC)</u> paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

#### **Contact Us**